| Title | Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck. |
| Publication Type | Journal Article |
| Year of Publication | 2022 |
| Authors | Kasi PMurtaza |
| Journal | Oncologist |
| Volume | 27 |
| Issue | 5 |
| Pagination | 336-337 |
| Date Published | 2022 May 06 |
| ISSN | 1549-490X |
| Keywords | Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Cetuximab, Colorectal Neoplasms, Head and Neck Neoplasms, Humans, Squamous Cell Carcinoma of Head and Neck |
| Abstract | This commentary highlights the article by Parikh and colleagues, regarding biweekly therapy with the anti-EGFR monoclonal antibody, cetuximab, for gastrointestinal cancer. |
| DOI | 10.1093/oncolo/oyac070 |
| Alternate Journal | Oncologist |
| PubMed ID | 35403691 |
| PubMed Central ID | PMC9074985 |